• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid improvement in a recurrent generalized pustular psoriasis patient ineffective to Ixekizumab following Spesolimab therapy.

作者信息

Li Wenjie, Cui Fan, Zhang Lixia, Yang Ge, Rang Zhen, Xu Minyan, Liu Yangying, Wang Siyu

机构信息

School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; Institute of Dermatology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.

Institute of Dermatology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.

出版信息

An Bras Dermatol. 2025 May-Jun;100(3):634-637. doi: 10.1016/j.abd.2024.09.003. Epub 2024 Dec 30.

DOI:10.1016/j.abd.2024.09.003
PMID:39741017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12234189/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbfa/12234189/29c87e446f56/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbfa/12234189/4150e3819d16/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbfa/12234189/bf40cafc91d2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbfa/12234189/29c87e446f56/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbfa/12234189/4150e3819d16/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbfa/12234189/bf40cafc91d2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbfa/12234189/29c87e446f56/gr3.jpg

相似文献

1
Rapid improvement in a recurrent generalized pustular psoriasis patient ineffective to Ixekizumab following Spesolimab therapy.司库奇尤单抗治疗无效的复发性泛发性脓疱型银屑病患者在接受斯佩索利单抗治疗后病情迅速改善。
An Bras Dermatol. 2025 May-Jun;100(3):634-637. doi: 10.1016/j.abd.2024.09.003. Epub 2024 Dec 30.
2
Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.斯帕利单抗治疗泛发性脓疱型银屑病亚洲患者的疗效和安全性：Effisayil™ 1 研究的随机、双盲、安慰剂对照结果。
J Dermatol. 2023 Feb;50(2):183-194. doi: 10.1111/1346-8138.16609. Epub 2022 Oct 25.
3
Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.在随机、安慰剂对照的 Effisayil 1 研究中，spesolimab 治疗泛发性脓疱型银屑病发作，可迅速和持续改善全身性脓疱性银屑病医师总体评估评分。
J Am Acad Dermatol. 2023 Jul;89(1):36-44. doi: 10.1016/j.jaad.2023.02.040. Epub 2023 Mar 2.
4
Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval.斯佩索利单抗治疗泛发性脓疱型银屑病：两项关键性临床试验的综述，支持该药在美国的初始监管批准。
Front Immunol. 2024 Jul 22;15:1359481. doi: 10.3389/fimmu.2024.1359481. eCollection 2024.
5
Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.Effisayil™ 2的设计：一项关于司帕索利单抗预防泛发性脓疱型银屑病患者病情发作的随机、双盲、安慰剂对照研究。
Dermatol Ther (Heidelb). 2023 Jan;13(1):347-359. doi: 10.1007/s13555-022-00835-6. Epub 2022 Nov 5.
6
Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).依奇珠单抗治疗红皮病型或泛发性脓疱型银屑病日本患者的长期疗效和安全性：一项开放标签、3 期研究（UNCOVER-J）的亚组分析。
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):325-332. doi: 10.1111/jdv.15287. Epub 2018 Nov 15.
7
Generalized pustular psoriasis successfully treated with spesolimab: A case report.司库奇尤单抗成功治疗泛发性脓疱型银屑病：一例报告
SAGE Open Med Case Rep. 2024 Feb 27;12:2050313X241235451. doi: 10.1177/2050313X241235451. eCollection 2024.
8
Generalized pustular psoriasis patient with a heterozygous hypomorphic MPO variant refractory to intravenous spesolimab.患有杂合性低功能MPO变异的泛发性脓疱型银屑病患者，对静脉注射司帕利单抗难治。
J Dermatol. 2025 Jan;52(1):167-170. doi: 10.1111/1346-8138.17464. Epub 2024 Sep 20.
9
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.脓疱型银屑病：全身性脓疱型银屑病中 spesolimab 的分子途径和作用。
J Allergy Clin Immunol. 2022 Apr;149(4):1402-1412. doi: 10.1016/j.jaci.2021.09.035. Epub 2021 Oct 20.
10
Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.在 Effisayil 1 研究中，spesolimab 治疗泛发性脓疱型银屑病发作的疗效在预先指定的患者亚组中。
Exp Dermatol. 2023 Aug;32(8):1279-1283. doi: 10.1111/exd.14824. Epub 2023 May 4.

本文引用的文献

1
Rapid response of spesolimab in biologics - failure patient with generalized pustular psoriasis flare.司妥昔单抗在生物制剂治疗失败的泛发性脓疱型银屑病发作患者中的快速反应
Postepy Dermatol Alergol. 2023 Aug;40(4):584-586. doi: 10.5114/ada.2023.129514. Epub 2023 Jul 15.
2
Rapid and sustained response to spesolimab in five Chinese patients with generalized pustular psoriasis.五例中国泛发性脓疱型银屑病患者对司库奇尤单抗的快速持续反应
Clin Exp Dermatol. 2023 Jul 7;48(7):803-805. doi: 10.1093/ced/llad108.
3
[Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab].
[白细胞介素-36受体抑制剂司帕索利单抗治疗下顽固性泛发性脓疱型银屑病的缓解]
Dermatologie (Heidelb). 2023 May;74(5):356-359. doi: 10.1007/s00105-023-05140-7. Epub 2023 Mar 21.
4
Trial of Spesolimab for Generalized Pustular Psoriasis.特索利单抗治疗泛发性脓疱型银屑病的试验。
N Engl J Med. 2021 Dec 23;385(26):2431-2440. doi: 10.1056/NEJMoa2111563.
5
Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP.日本泛发性脓疱性银屑病管理与治疗指南：GPP 的新发病机制与治疗。
J Dermatol. 2018 Nov;45(11):1235-1270. doi: 10.1111/1346-8138.14523. Epub 2018 Sep 19.
6
IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.白细胞介素-1和白细胞介素-36是泛发性脓疱型银屑病中的主要细胞因子。
J Allergy Clin Immunol. 2017 Jul;140(1):109-120. doi: 10.1016/j.jaci.2016.08.056. Epub 2016 Dec 31.